The initial success of the copyright undeniably reshaped the medication landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. While early earnings were significant, the end of patents and the appearance of less expensive alternatives have weakened market share. Therefore, a thorough assessment of on